Prazosin
alpha-Adrenergic Blocker
NADAC/unit
$0.0854
No Shortage
Tier 1: 91.2%
9 Manufacturers
27 ANDAs
Active Shortages
2023-04-28 Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023, Pfizer Inc.
2023-04-28 Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023, Pfizer Inc.
2023-04-28 Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023, Pfizer Inc.
Market Intelligence
2025-11-05 Class II Recall: Teva Pharmaceuticals USA, Inc
2025-11-05 Class II Recall: Teva Pharmaceuticals USA, Inc
2025-11-05 Class II Recall: Amerisource Health Services LLC
2025-11-05 Class II Recall: Amerisource Health Services LLC
2025-11-05 Class II Recall: Amerisource Health Services LLC
Generic Manufacturers
ALEMBIC PHARMACEUTICALS LTDAPPCO PHARMA LLCAUROBINDO PHARMA LTDGRANULES PHARMACEUTICALS INCMANKIND PHARMA LTDMSN LABORATORIES PRIVATE LTDMYLAN PHARMACEUTICALS INCNOVITIUM PHARMA LLCPFIZER LABORATORIES DIV PFIZER INCTEVA PHARMACEUTICALS USA
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.